Skip to content Skip to footer
Subscribe Now

VIEWPOINTS

VIEWPOINTS_Andrea Mugan_2023
Andrea Mugan, Global Franchise Head of DDR & GYN/GU Cancers, AstraZeneca Shares Insights on ‘Never Miss’ campaign
Shots: Andrea briefed PharmaShots about the global prostate cancer awareness ‘Never Miss’ campaign developed by AstraZeneca and MSD to help men understand their potential risk of developing prostate cancer He also talked about the increasing number of prostate cancer patients and how this campaign will help support those who may be impacted by prostate cancer…
June 22, 2023
VIEWPOINTS_John Orwin_2023
John Orwin, President, and CEO at Atreca Shares his Views on Developing Novel Therapies for Cancer
Shots: John spoke about the development of a T cell engaging bispecific antibody directed against a novel solid tumor target under Atreca’s existing collaboration with Xencor He also talked about how this joint program combines the Atreca-discovered antibody, APN-346958, with Xencor’s XmAb CD3 bispecific antibody platform The interview gives an understanding of Atreca’s focus on…
June 20, 2023
VIEWPOINTS_Philippe Halfon_2023
Philippe Halfon, President & Founder of Genoscience Pharma Shares Insights from the P-IIb Trial of Ezurpimtrostat to Treat Hepatocarcinoma
Shots: Philippe talked about the launch of the ABE-LIVER P-IIb study evaluating Ezurpimtrostat to treat hepatocarcinoma in combination with atezolizumab (an anti-PDL1) and bevacizumab (an antiangiogenic agent) He also gave a brief on the study design and talked about the efficacy of Ezurpimtrostat with atezolizumab & bevacizumab, compared to SOC alone The interview gives an…
June 15, 2023
VIEWPOINTS_Rui Avelar_2023
Rui Avelar, CMO and Head of R&D at Evolus Shares Insights from Interim P-II Data Results Evaluating an “Extra-Strength” Formulation of Jeuveau
Shots: Rui gave the details about the “extra-strength” formulation of Jeuveau. He highlighted the study design and results of the trial evaluating  Jeuveau. The data indicated that the “extra-strength” formulation of Jeuveau at 40U achieved a duration profile of 6 months or 26 weeks The data was presented at the 2023 IMCAS World Congress in…
June 13, 2023
VIEWPOINTS_Eric Halioua_2023
Eric Halioua, President & CEO at PDC*line Pharma Shares Insights on the Results from P-I/II Trial with PDC*lung01
Shots: Eric shared the results from the first immunological results of its PDC-LUNG-101 P-I/II trial with PDC*lung01 which is the company’s cancer vaccine candidate for Non-Small Cell Lung Cancer The results were presented at ESMO-IO 2022 elaborating on the safety, tolerability, immunogenicity, and preliminary clinical activity of the drug candidate The interview shows PDC*line’s vision…
June 1, 2023
VIEWPOINTS_Monica Mann_2023
Monica Mann, VP, of Medical Affairs for Global MS and Pipeline at Biogen Shares Insights on New Data on MS Therapies and Digital Health Research
Shots: Monica spoke about the new data from its multiple sclerosis therapies portfolio presented at the 38th ECTRIMS meeting The highlights from the presentation were the safety and efficacy results of Vumerity, patient-reported outcomes from the treatment with Tysabri, and posters highlighting advances in digital health initiatives The interview shows how Biogen develops, and delivers…
May 31, 2023
Load more